International Journal of Laboratory Hematology

Volume 45, Issue 5 pp. 758-765

ORIGINAL ARTICLE

Evaluation of two fully automated ADAMTS13 activity assays in comparison to manual FRET assay

Christian Irsara,

Christian Irsara

orcid.org/0000-0003-4901-8861

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Markus Anliker,

Markus Anliker

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Alexander E. Egger,

Alexander E. Egger

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Lukas Harasser,

Lukas Harasser

Department of Internal Medicine IV, Nephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria

Search for more papers by this author

Karl Lhotta,

Karl Lhotta

Department of Internal Medicine III, Nephrology and Dialysis, Academic Teaching Hospital Feldkirch, Feldkirch, Austria

Search for more papers by this author

Clemens Feistritzer,

Clemens Feistritzer

Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Andrea Griesmacher,

Andrea Griesmacher

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Lorin Loacker,

Corresponding Author

Lorin Loacker

[email protected]

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Correspondence

Lorin Loacker, Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.

Email: [email protected]

Search for more papers by this author

Christian Irsara,

Christian Irsara

orcid.org/0000-0003-4901-8861

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Markus Anliker,

Markus Anliker

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Alexander E. Egger,

Alexander E. Egger

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Lukas Harasser,

Lukas Harasser

Department of Internal Medicine IV, Nephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria

Search for more papers by this author

Karl Lhotta,

Karl Lhotta

Department of Internal Medicine III, Nephrology and Dialysis, Academic Teaching Hospital Feldkirch, Feldkirch, Austria

Search for more papers by this author

Clemens Feistritzer,

Clemens Feistritzer

Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Andrea Griesmacher,

Andrea Griesmacher

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Search for more papers by this author

Lorin Loacker,

Corresponding Author

Lorin Loacker

[email protected]

Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Correspondence

Lorin Loacker, Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.

Email: [email protected]

Search for more papers by this author

First published: 17 May 2023

https://doi.org/10.1111/ijlh.14090

Citations: 1

Share a link

Email
Wechat
Bluesky

Abstract

Introduction

The objective of the present study was to evaluate and compare the validity and utility of two fully automated ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity assays for clinical diagnostic decision-making and to compare their performance.

Methods

Two automated ADAMTS13 activity assays (Werfen HemosIL® AcuStar ADAMTS13 Activity, Technoclone Technofluor ADAMTS13 Activity) were compared with a manual FRET assay (BioMedica ACTIFLUOR ADAMTS13 Activity). The following samples were used: 13 acute phase TTP (thrombotic thrombocytopenic purpura) samples from 11 different patients, one sample from a patient with congenital ADAMTS13 deficiency, 16 samples from control patients, three follow-up samples from TTP patients in long-term remission and one sample from a patient with stem cell transplantation related thrombotic microangiopathy (TMA). The WHO 1st International Standard for ADAMTS13 and several dilutions of normal plasma with ADAMTS13-depleted normal plasma were also tested. Statistical analysis included descriptive statistics, sensitivity and specificity, Passing & Bablok regression and Bland–Altman plot.

Results

The quantitative comparison between the HemosIL® (x) and Technofluor (y) methods showed a strong correlation (Pearson r = 0.98, n = 49). When considering an ADAMTS13 activity of <10% as a hallmark for the diagnosis of TTP, two fully automated assays were both able to identify all TTP- and non-TTP-samples correctly, resulting in sensitivities and specificities of 100%.

Conclusion

Both fully automated ADAMTS13 activity assays showed a good diagnostic performance and quantitative correlation among themselves, discriminating reliably between TTP- and non-TTP-patients.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

Open Research

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supporting Information

REFERENCES

1Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67: 395-424.
10.1146/annurev.biochem.67.1.395
CAS PubMed Web of Science® Google Scholar
2Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017; 1(10): 590-600.
10.1182/bloodadvances.2017005124
CAS PubMed Web of Science® Google Scholar
3Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413(6855): 488-494.
10.1038/35097008
CAS PubMed Web of Science® Google Scholar
4Favaloro EJ, Pasalic L, Henry B, Lippi G. Laboratory testing for ADAMTS13: utility for TTP diagnosis/exclusion and beyond. Am J Hematol. 2021; 96(8): 1049-1055.
10.1002/ajh.26241
CAS PubMed Web of Science® Google Scholar
5Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017; 129(21): 2836-2846.
10.1182/blood-2016-10-709857
CAS PubMed Web of Science® Google Scholar
6Li A, Khalighi PR, Wu Q, Garcia DA. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2018; 16(1): 164-169.
10.1111/jth.13882
CAS PubMed Web of Science® Google Scholar
7Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008; 93(2): 232-239.
10.3324/haematol.11739
CAS PubMed Web of Science® Google Scholar
8Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol. 2008; 141(5): 651-658.
10.1111/j.1365-2141.2008.07107.x
CAS PubMed Web of Science® Google Scholar
9Dekimpe C, Roose E, Kangro K, et al. Determination of anti-ADAMTS-13 autoantibody titers in ELISA: influence of ADAMTS-13 presentation and autoantibody detection. J Thromb Haemost. 2021; 19(9): 2248-2255.
10.1111/jth.15297
CAS PubMed Web of Science® Google Scholar
10Thomas W, Cutler JA, Moore GW, McDonald V, Hunt BJ. The utility of a fast turnaround ADAMTS13 activity in the diagnosis and exclusion of thrombotic thrombocytopenic purpura. Br J Haematol. 2019; 184(6): 1026-1032.
10.1111/bjh.15219
PubMed Web of Science® Google Scholar
11Alwan F, Vendramin C, Vanhoorelbeke K, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017; 130(4): 466-471.
10.1182/blood-2016-12-758656
CAS PubMed Web of Science® Google Scholar
12Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999; 82(5): 1386-1389.
10.1055/s-0037-1614780
CAS PubMed Web of Science® Google Scholar
13Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol. 2002; 81(8): 430-435.
10.1007/s00277-002-0502-3
CAS PubMed Web of Science® Google Scholar
14Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost. 1999; 82(5): 1382-1385.
10.1055/s-0037-1614779
CAS PubMed Web of Science® Google Scholar
15Joly B, Stepanian A, Hajage D, et al. Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. Thromb Res. 2014; 134(5): 1074-1080.
10.1016/j.thromres.2014.09.006
CAS PubMed Web of Science® Google Scholar
16Thouzeau S, Capdenat S, Stepanian A, Coppo P, Veyradier A. Evaluation of a commercial assay for ADAMTS13 activity measurement. Thromb Haemost. 2013; 110(4): 852-853.
10.1160/TH13-05-0393
CAS PubMed Web of Science® Google Scholar
17Rieger M, Ferrari S, Kremer Hovinga JA, et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost. 2006; 95(2): 212-220.
10.1160/TH05-08-0550
CAS PubMed Web of Science® Google Scholar
18Vendramin C, Thomas M, Westwood JP, Scully M. Bethesda assay for detecting inhibitory anti-ADAMTS13 antibodies in immune-mediated thrombotic thrombocytopenic purpura. TH Open. 2018; 2(3): e329-e333.
10.1055/s-0038-1672187
PubMed Google Scholar
19Smock KJ. ADAMTS13 testing update: focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies. Int J Lab Hematol. 2021; 43(Suppl 1): 103-108.
10.1111/ijlh.13557
PubMed Web of Science® Google Scholar
20Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339(22): 1578-1584.
10.1056/NEJM199811263392202
CAS PubMed Web of Science® Google Scholar
21Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339(22): 1585-1594.
10.1056/NEJM199811263392203
CAS PubMed Web of Science® Google Scholar
22Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005; 129(1): 93-100.
10.1111/j.1365-2141.2005.05420.x
CAS PubMed Web of Science® Google Scholar
23Beranger N, Benghezal S, Joly BS, et al. Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay. Res Pract Thromb Haemost. 2021; 5(1): 81-93.
10.1002/rth2.12461
CAS PubMed Web of Science® Google Scholar
24Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019; 380(4): 335-346.
10.1056/NEJMoa1806311
CAS PubMed Web of Science® Google Scholar
25Volker LA, Kaufeld J, Miesbach W, et al. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP. Blood Adv. 2020; 4(13): 3093-3101.
10.1182/bloodadvances.2020001987
PubMed Web of Science® Google Scholar
26Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021; 137(14): 1855-1861.
10.1182/blood.2020009150
CAS PubMed Web of Science® Google Scholar
27Valsecchi C, Mirabet M, Mancini I, et al. Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 activity. Thromb Haemost. 2019; 119(11): 1767-1772.
10.1055/s-0039-1696718
PubMed Web of Science® Google Scholar
28Falcinelli E, Baccolo A, Mezzasoma AM, Gresele P. Comparative evaluation of the fully automated HemosIL((R)) AcuStar ADAMTS13 activity assay vs. ELISA: possible interference by autoantibodies different from anti ADAMTS-13. Clin Chem Lab Med. 2021; 59(5): e193-e196.
10.1515/cclm-2020-1020
CAS PubMed Web of Science® Google Scholar
29Jacquemin M, Van Horenbeeck I, Debasse M, et al. Optimization of the detection of inhibitory autoantibodies against the VWF-cleaving protease ADAMTS13 with an automated chemiluminescent ADAMTS13 activity immunoassay. Int J Lab Hematol. 2021; 43(2): 290-297.
10.1111/ijlh.13359
PubMed Web of Science® Google Scholar
30Favresse J, Lardinois B, Chatelain B, Jacqmin H, Mullier F. Evaluation of the fully automated HemosIL Acustar ADAMTS13 activity assay. Thromb Haemost. 2018; 118(5): 942-944.
10.1055/s-0038-1641151
PubMed Web of Science® Google Scholar
31Stratmann J, Ward JN, Miesbach W. Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study. J Thromb Thrombolysis. 2020; 50(3): 628-631.
10.1007/s11239-020-02086-8
CAS PubMed Web of Science® Google Scholar
32Singh D, Subhan MO, de Groot R, et al. ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura (TTP). Res Pract Thromb Haemost. 2023; 7:100108.
10.1016/j.rpth.2023.100108
PubMed Web of Science® Google Scholar
33Turecek PL, Peck RC, Rangarajan S, et al. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb Res. 2021; 201: 100-112.
10.1016/j.thromres.2021.02.012
CAS PubMed Web of Science® Google Scholar
34Mackie I, Langley K, Chitolie A, et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost. 2013; 109(3): 488-496.
10.1160/TH12-08-0565
CAS PubMed Web of Science® Google Scholar
35Nakashima MO, Zhang X, Rogers HJ, et al. Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test. Int J Lab Hematol. 2016; 38(5): 550-559.
10.1111/ijlh.12542
CAS PubMed Web of Science® Google Scholar
36Tsai HM, Raoufi M, Zhou W, et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2006; 95(5): 886-892.
10.1160/TH06-02-0100
CAS PubMed Web of Science® Google Scholar
37Lee HT, Park UB, Jeong TJ, et al. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP. Biochem Biophys Res Commun. 2021; 27(567): 49-55.
10.1016/j.bbrc.2021.06.030
Web of Science® Google Scholar
38Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18(10): 2486-2495.
10.1111/jth.15006
PubMed Web of Science® Google Scholar
39Haem SC. Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019. J Thromb Haemost. 2022; 20(6): 1428-1436.
10.1111/jth.15681
PubMed Web of Science® Google Scholar
40Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost. 2007; 5(4): 866-867.
10.1111/j.1538-7836.2007.02438.x
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume45, Issue5

October 2023

Pages 758-765

Evaluation of two fully automated ADAMTS13 activity assays in comparison to manual FRET assay

Abstract

Introduction

Methods

Results

Conclusion

CONFLICT OF INTEREST STATEMENT

Open Research

DATA AVAILABILITY STATEMENT

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Evaluation of two fully automated ADAMTS13 activity assays in comparison to manual FRET assay

Abstract

Introduction

Methods

Results

Conclusion

CONFLICT OF INTEREST STATEMENT

Open Research

DATA AVAILABILITY STATEMENT

Supporting Information

REFERENCES

Citing Literature

References

Related

Information